Clinical Research Directory
Browse clinical research sites, groups, and studies.
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:
Sponsor: Centre Francois Baclesse
Summary
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Official title: Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
116
Start Date
2025-04-30
Completion Date
2028-09-30
Last Updated
2025-10-07
Healthy Volunteers
No
Interventions
transcutaneous auricular vagus nerve stimulation
The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles). The dispositive is used every day at home, twice daily (during 30 minutes)
Placebo device
The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles). The dispositive is used every day at home, twice daily (during 30 minutes)
Locations (4)
Centre François Baclesse
Caen, France
CHU CAEN
Caen, France
Centre Oscar Lambret
Lille, France
Centre Henri Becquerel
Rouen, France